MDS Pharma Services expanded its presence in the Phoenix area with a new 300-bed Phase I facility in nearby Tempe, Ariz. The $25 million facility more than doubles the previous MDS Phase I capacity in Phoenix to 420 total beds to meet the growing needs of its pharmaceutical and biotech clients. The new facility brings the MDS Pharma Services global total to more than 1,100 beds.

In addition to a specialized area for conducting cardiac safety trials, the new facility also offers specialized ophthalmic capabilities, as well as a range of other specialty Phase I services. Purpose-built from the ground up to be a Phase I clinic, the new facility has a state-of-the art clinical lab and secure pharmacy, accommodations for study participants and areas for visiting clients.

The workforce for the new facility is drawn from the same experienced team that operated the earlier MDS Pharma Services Phoenix clinic, where they achieved a better than 97% on-time study start-up record, according to the company.

Release Date: January 25, 2008
Source: MDS Pharma Services